Evasin-displaying lactic acid bacteria bind different chemokines and neutralize CXCL8 production in Caco-2 cells

Microbial Biotechnology

Volumn 10, Issue 6, 2017, Pages 1732-1743

  Škrlec, Katja ^a,b   Pucer Janež, Anja ^a   Rogelj, Boris ^a,b,c   Štrukelj, Borut ^a,b   Berlec, Aleš ^a  

^a JO EF STEFAN INSTITUTE   (Slovenia)

^b UNIVERSITY OF LJUBLJANA   (Slovenia)

^c Biomedical Research Institute BRIS   (Slovenia)

Author keywords

[No Author keywords available]

Indexed keywords

BINDING PROTEIN; EVASIN 3; EVASIN FUSION PROTEIN; HYBRID PROTEIN; INTERLEUKIN 8; UNCLASSIFIED DRUG; ALPHA CHEMOKINE; CHEMOKINE RECEPTOR CXCR; PROTEIN BINDING;

ARTICLE; BACTERIAL GENE; BACTERIUM ADHERENCE; CACO-2 CELL LINE; CELL SURFACE DISPLAY; CONTROLLED STUDY; CYTOKINE PRODUCTION; ENZYME LINKED IMMUNOSORBENT ASSAY; EVASIN GENE; GENE OVEREXPRESSION; LACTOBACILLUS SALIVARIUS; LACTOCOCCUS LACTIS; MOLECULAR CLONING; NONHUMAN; PROTEIN EXPRESSION; TIME; GENE EXPRESSION; GENETICS; HUMAN; INTESTINE; METABOLISM; MICROBIOLOGY;

CACO-2 CELLS; CHEMOKINES, CXC; GENE EXPRESSION; HUMANS; INTERLEUKIN-8; INTESTINES; LACTOCOCCUS LACTIS; PROTEIN BINDING; RECEPTORS, CXCR;

EID: 85032385376     PISSN: 17517907     EISSN: 17517915     Source Type: Journal    
DOI: 10.1111/1751-7915.12781     Document Type: Article

References (57)

1. Ajuebor, M.N., and Swain, M.G. (2002) Role of chemokines and chemokine receptors in the gastrointestinal tract. Immunology 105: 137–143.
2. Allegretti, M., Cesta, M.C., Garin, A., and Proudfoot, A.E. (2012) Current status of chemokine receptor inhibitors in development. Immunol Lett 145: 68–78.
3. van Asseldonk, M., Rutten, G., Oteman, M., Siezen, R.J., de Vos, W.M., and Simons, G. (1990) Cloning of usp45, a gene encoding a secreted protein from Lactococcus lactis subsp. lactis MG1363. Gene 95: 155–160.
4. Atreya, R., and Neurath, M.F. (2010) Chemokines in inflammatory bowel diseases. Dig Dis 28: 386–394.
5. Back, A., Borges, F., Mangavel, C., Paris, C., Rondags, E., Kapel, R., et al. (2016) Recombinant pediocin in Lactococcus lactis: increased production by propeptide fusion and improved potency by co-production with PedC. Microb Biotechnol 9: 466–477.
6. Baier, P.K., Eggstein, S., Wolff-Vorbeck, G., Baumgartner, U., and Hopt, U.T. (2005) Chemokines in human colorectal carcinoma. Anticancer Res 25: 3581–3584.
7. Berlec, A., Ravnikar, M., and Strukelj, B. (2012) Lactic acid bacteria as oral delivery systems for biomolecules. Pharmazie 67: 891–898.
8. Berlec, A., Perse, M., Ravnikar, M., Lunder, M., Erman, A., Cerar, A., and Strukelj, B. (2016) Dextran sulphate sodium colitis in C57BL/6J mice is alleviated by Lactococcus lactis and worsened by the neutralization of Tumor necrosis Factor alpha. Int Immunopharmacol 43: 219–226.
9. Bonvin, P., Dunn, S.M., Rousseau, F., Dyer, D.P., Shaw, J., Power, C.A., et al. (2014) Identification of the pharmacophore of the CC chemokine-binding proteins Evasin-1 and -4 using phage display. J Biol Chem 289: 31846–31855.
10. Bonvin, P., Power, C.A., and Proudfoot, A.E. (2016) Evasins: therapeutic potential of a new family of chemokine-binding proteins from ticks. Front Immunol 7: 208.
11. Bosma, T., Kanninga, R., Neef, J., Audouy, S.A., van Roosmalen, M.L., Steen, A., et al. (2006) Novel surface display system for proteins on non-genetically modified gram-positive bacteria. Appl Environ Microbiol 72: 880–889.
12. Braunersreuther, V., Montecucco, F., Pelli, G., Galan, K., Proudfoot, A.E., Belin, A., et al. (2013) Treatment with the CC chemokine-binding protein Evasin-4 improves post-infarction myocardial injury and survival in mice. Thromb Haemost 110: 807–825.
13. Buist, G., Kok, J., Leenhouts, K.J., Dabrowska, M., Venema, G., and Haandrikman, A.J. (1995) Molecular cloning and nucleotide sequence of the gene encoding the major peptidoglycan hydrolase of Lactococcus lactis, a muramidase needed for cell separation. J Bacteriol 177: 1554–1563.
14. Castellani, M.L., Bhattacharya, K., Tagen, M., Kempuraj, D., Perrella, A., De Lutiis, M., et al. (2007) Anti-chemokine therapy for inflammatory diseases. Int J Immunopathol Pharmacol 20: 447–453.
15. Castor, M.G., Rezende, B., Resende, C.B., Alessandri, A.L., Fagundes, C.T., Sousa, L.P., et al. (2010) The CCL3/macrophage inflammatory protein-1 alpha-binding protein evasin-1 protects from graft-versus-host disease but does not modify graft-versus-leukemia in mice. J Immunol 184: 2646–2654.
16. Copin, J.C., da Silva, R.F., Fraga-Silva, R.A., Capettini, L., Quintao, S., Lenglet, S., et al. (2013) Treatment with Evasin-3 reduces atherosclerotic vulnerability for ischemic stroke, but not brain injury in mice. J Cereb Blood Flow Metab 33: 490–498.
17. Cortes-Perez, N.G., Poquet, I., Oliveira, M., Gratadoux, J.J., Madsen, S.M., Miyoshi, A., et al. (2006) Construction and characterization of a Lactococcus lactis strain deficient in intracellular ClpP and extracellular HtrA proteases. Microbiol 152: 2611–2618.
18. Davey, L., Halperin, S.A., and Lee, S.F. (2016) Thiol-disulfide exchange in Gram-positive Firmicutes. Trends Microbiol 24: 902–915.
19. de Moreno de LeBlanc, A., Del Carmen, S., Chatel, J.M., Miyoshi, A., Azevedo, V., Langella, P., et al. (2015) Current review of genetically modified lactic acid bacteria for the prevention and treatment of colitis using murine models. Gastroenterol Res Pract 2015: 146972.
20. Deruaz, M., Frauenschuh, A., Alessandri, A.L., Dias, J.M., Coelho, F.M., Russo, R.C., et al. (2008) Ticks produce highly selective chemokine binding proteins with antiinflammatory activity. J Exp Med 205: 2019–2031.
21. Deruaz, M., Bonvin, P., Severin, I.C., Johnson, Z., Krohn, S., Power, C.A., and Proudfoot, A.E. (2013) Evasin-4, a tick-derived chemokine-binding protein with broad selectivity can be modified for use in preclinical disease models. FEBS J 280: 4876–4887.
22. Diaz, M.A., Bik, E.M., Carlin, K.P., Venn-Watson, S.K., Jensen, E.D., Jones, S.E., et al. (2013) Identification of Lactobacillus strains with probiotic features from the bottlenose dolphin (Tursiops truncatus). J Appl Microbiol 115: 1037–1051.
23. Frauenschuh, A., Power, C.A., Deruaz, M., Ferreira, B.R., Silva, J.S., Teixeira, M.M., et al. (2007) Molecular cloning and characterization of a highly selective chemokine-binding protein from the tick Rhipicephalus sanguineus. J Biol Chem 282: 27250–27258.
24. Gonzalez-Motos, V., Kropp, K.A., and Viejo-Borbolla, A. (2016) Chemokine binding proteins: an immunomodulatory strategy going viral. Cytokine Growth Factor Rev 30: 71–80.
25. Han, W., Mercenier, A., Ait-Belgnaoui, A., Pavan, S., Lamine, F., Van Swam, I.I., et al. (2006) Improvement of an experimental colitis in rats by lactic acid bacteria producing superoxide dismutase. Inflamm Bowel Dis 12: 1044–1052.
26. Ina, K., Kusugami, K., Yamaguchi, T., Imada, A., Hosokawa, T., Ohsuga, M., et al. (1997) Mucosal interleukin-8 is involved in neutrophil migration and binding to extracellular matrix in inflammatory bowel disease. Am J Gastroenterol 92: 1342–1346.
27. Kleerebezem, M., and de Vos, W.M. (2011) Lactic acid bacteria: life after genomics. Microb Biotechnol 4: 318–322.
28. Koelink, P.J., Overbeek, S.A., Braber, S., de Kruijf, P., Folkerts, G., Smit, M.J., and Kraneveld, A.D. (2012) Targeting chemokine receptors in chronic inflammatory diseases: an extensive review. Pharmacol Ther 133: 1–18.
29. Kosler, S., Strukelj, B., and Berlec, A. (2017) Lactic acid bacteria with concomitant IL-17, IL-23 and TNFalpha- binding ability for the treatment of inflammatory bowel disease. Curr Pharm Biotechnol 18: 318–326.
30. Kuipers, O.P., de Ruyter, P.G.G.A., Kleerebezem, M., and de Vos, W.M. (1998) Quorum sensing-controlled gene expression in lactic acid bacteria. J Biotechnol 64: 15–21.
31. Lindholm, A., Smeds, A., and Palva, A. (2004) Receptor binding domain of Escherichia coli F18 fimbrial adhesin FedF can be both efficiently secreted and surface displayed in a functional form in Lactococcus lactis. Appl Environ Microbiol 70: 2061–2071.
32. Luerce, T.D., Gomes-Santos, A.C., Rocha, C.S., Moreira, T.G., Cruz, D.N., Lemos, L., et al. (2014) Anti-inflammatory effects of Lactococcus lactis NCDO 2118 during the remission period of chemically induced colitis. Gut Pathog 6: 33.
33. Mierau, I., and Kleerebezem, M. (2005) 10 years of the nisin-controlled gene expression system (NICE) in Lactococcus lactis. Appl Microbiol Biotechnol 68: 705–717.
34. Montecucco, F., Mach, F., Lenglet, S., Vonlaufen, A., Gomes Quindere, A.L., Pelli, G., et al. (2014) Treatment with Evasin-3 abrogates neutrophil-mediated inflammation in mouse acute pancreatitis. Eur J Clin Invest 44: 940–950.
35. Ng, S.C., Hart, A.L., Kamm, M.A., Stagg, A.J., and Knight, S.C. (2009) Mechanisms of action of probiotics: recent advances. Inflamm Bowel Dis 15: 300–310.
36. Poquet, I., Saint, V., Seznec, E., Simoes, N., Bolotin, A., and Gruss, A. (2000) HtrA is the unique surface housekeeping protease in Lactococcus lactis and is required for natural protein processing. Mol Microbiol 35: 1042–1051.
37. Proudfoot, A.E., Power, C.A., and Schwarz, M.K. (2010) Anti-chemokine small molecule drugs: a promising future? Expert Opin Investig Drugs 19: 345–355.
38. Proudfoot, A.E., Bonvin, P., and Power, C.A. (2015) Targeting chemokines: pathogens can, why can't we? Cytokine 74: 259–267.
39. Raab, Y., Gerdin, B., Ahlstedt, S., and Hallgren, R. (1993) Neutrophil mucosal involvement is accompanied by enhanced local production of interleukin-8 in ulcerative colitis. Gut 34: 1203–1206.
40. Ravnikar, M., Strukelj, B., Obermajer, N., Lunder, M., and Berlec, A. (2010) Engineered lactic acid bacterium Lactococcus lactis capable of binding antibodies and tumor necrosis factor alpha. Appl Environ Microbiol 76: 6928–6932.
41. Russo, R.C., Alessandri, A.L., Garcia, C.C., Cordeiro, B.F., Pinho, V., Cassali, G.D., et al. (2011) Therapeutic effects of evasin-1, a chemokine binding protein, in bleomycin-induced pulmonary fibrosis. Am J Respir Cell Mol Biol 45: 72–80.
42. de Ruyter, P.G., Kuipers, O.P., and de Vos, W.M. (1996) Controlled gene expression systems for Lactococcus lactis with the food-grade inducer nisin. Appl Environ Microbiol 62: 3662–3667.
43. Schotte, L., Steidler, L., Vandekerckhove, J., and Remaut, E. (2000) Secretion of biologically active murine interleukin-10 by Lactococcus lactis. Enzyme Microb Technol 27: 761–765.
44. Sebastian, S., Hernández, V., Myrelid, P., Kariv, R., Tsianos, E., Toruner, M., et al. (2014) Colorectal cancer in inflammatory bowel disease: results of the 3rd ECCO pathogenesis scientific workshop (I). J Crohn Colitis 8: 5–18.
45. Seet, B.T., and McFadden, G. (2002) Viral chemokine-binding proteins. J Leukoc Biol 72: 24–34.
46. Steen, A., Buist, G., Leenhouts, K.J., El Khattabi, M., Grijpstra, F., Zomer, A.L., et al. (2003) Cell wall attachment of a widely distributed peptidoglycan binding domain is hindered by cell wall constituents. J Biol Chem 278: 23874–23881.
47. Steen, A., Larsen, O., Thiele, S., and Rosenkilde, M.M. (2014) Biased and G protein-independent signaling of chemokine receptors. Front Immunol 5: 277.
48. Triantafillidis, J.K., Nasioulas, G., and Kosmidis, P.A. (2009) Colorectal cancer and inflammatory bowel disease: epidemiology, risk factors, mechanisms of carcinogenesis and prevention strategies. Anticancer Res 29: 2727–2737.
49. Triantafillidis, J.K., Merikas, E., and Georgopoulos, F. (2011) Current and emerging drugs for the treatment of inflammatory bowel disease. Drug Des Devel Ther 5: 185–210.
50. Trinh, R., Gurbaxani, B., Morrison, S.L., and Seyfzadeh, M. (2004) Optimization of codon pair use within the (GGGGS)3 linker sequence results in enhanced protein expression. Mol Immunol 40: 717–722.
51. Vandenbroucke, K., de Haard, H., Beirnaert, E., Dreier, T., Lauwereys, M., Huyck, L., et al. (2010) Orally administered L. lactis secreting an anti-TNF Nanobody demonstrate efficacy in chronic colitis. Mucosal Immunol 3: 49–56.
52. Wang, D., Dubois, R.N., and Richmond, A. (2009) The role of chemokines in intestinal inflammation and cancer. Curr Opin Pharmacol 9: 688–696.
53. Zadravec, P., Mavric, A., Bogovic Matijasic, B., Strukelj, B., and Berlec, A. (2014) Engineering BmpA as a carrier for surface display of IgG-binding domain on Lactococcus lactis. Protein Eng Des Sel 27: 21–27.
54. Zadravec, P., Strukelj, B., and Berlec, A. (2015a) Heterologous surface display on lactic acid bacteria: non-GMO alternative? Bioengineered 6: 179–183.
55. Zadravec, P., Strukelj, B., and Berlec, A. (2015b) Improvement of LysM-mediated surface display of designed ankyrin repeat proteins (DARPins) in recombinant and nonrecombinant strains of Lactococcus lactis and Lactobacillus species. Appl Environ Microbiol 81: 2098–2106.
56. Zadravec, P., Mareckova, L., Petrokova, H., Hodnik, V., Perisic Nanut, M., Anderluh, G., et al. (2016) Development of recombinant Lactococcus lactis displaying albumin-binding domain variants against Shiga toxin 1 B subunit. PLoS ONE 11: e0162625.
57. Zlotnik, A., and Yoshie, O. (2000) Chemokines: a new classification system and their role in immunity. Immunity 12: 121–127.